ERBB2 and gastric cancer: In February 2019, the US FDA approved TAS-102 in patients with advanced GC previously treated with at least 2 prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2-targeted therapy.